Meiyouheng (Becotatug Vedotin)

Meiyouheng (becotatug vedotin) is an antibody-drug conjugate (ADC) that targets the epidermal growth factor receptor (EGFR). It is the first EGFR-targeted ADC to receive marketing approval, and it is approved for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) who have failed at least two lines of systemic chemotherapy and prior PD-1/PD-L1 (anti-PD-(L)1) inhibitor therapy.

Becotatug vedotin is built from three parts: an EGFR-targeted humanized monoclonal antibody, a potent microtubule-inhibiting payload called monomethyl auristatin E (MMAE), and a valine-citrulline linker that joins them. The antibody binds with high affinity to EGFR on the surface of tumor cells. Once the ADC is internalized by the cancer cell, lysosomal enzymes cleave the linker and release the MMAE payload inside the cell, which disrupts the cell’s microtubules and leads to tumor cell death. By delivering the cytotoxic payload directly to EGFR-expressing tumor cells, the ADC is designed to concentrate its effect on cancer cells.

It is a prescription medicine and must be used under the supervision of a qualified oncologist.

Recommended Dosage:
In clinical use, Meiyouheng is administered as an intravenous (IV) infusion at a dose of 2.3 mg/kg once every 3 weeks (Q3W), on day 1 of each 21-day cycle. Treatment is continued until there is evidence of disease progression, unacceptable toxicity, or withdrawal of consent.

The treating physician determines the appropriate dose, infusion schedule, dose interruptions, and dose reductions based on the patient’s body weight, tolerability, and the approved product information. Meiyouheng is given by a healthcare professional in a clinical setting; patients should not self-administer. Patients should follow their oncologist’s instructions and report any side effects promptly.

• Because becotatug vedotin contains an MMAE payload, some patients may develop numbness, tingling, reduced sensation, or weakness in the hands or feet. Inform your physician promptly if these symptoms appear or worsen, as treatment changes or supportive care may be needed.
• Skin-related side effects, including rash and itching (pruritus), are among the most commonly reported reactions. Patients should tell their physician if these symptoms become severe, persistent, or uncomfortable so they can receive appropriate treatment and supportive care.
• Becotatug vedotin may reduce white blood cell counts, increasing the risk of infection. Your physician may recommend regular blood tests during treatment to monitor blood counts and help ensure the medicine continues to be used safely.
• Some patients may experience additional side effects during treatment. If you notice any persistent, severe, or unusual symptoms, contact your physician promptly. Clinical studies found the overall safety profile to be manageable, with no treatment-related deaths reported.
• Before starting becotatug vedotin, tell your physician about all prescription medicines, over-the-counter products, vitamins, and herbal supplements you use. This helps identify possible drug interactions and allows your healthcare provider to manage your treatment more safely.
• There is limited information about the use of becotatug vedotin during pregnancy or breastfeeding. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the potential risks and benefits with their treating physician before beginning treatment.

What documents are required to import MEIYOUHENG to India?

MEIYOUHENG (becotatug vedotin injection) may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a qualified doctor
• The patient’s diagnostic reports
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and an import permit, if applicable.

Is MEIYOUHENG available in India?

MEIYOUHENG (becotatug vedotin injection) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of the current publicly available information, MEIYOUHENG is not commercially marketed in India.

However, patients in India can legally access MEIYOUHENG through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Meiyouheng in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE)
• Meiyouheng price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
• Ensuring full transparency throughout the process

MEIYOUHENG can be made available to patients, doctors, and hospitals in Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only after receipt of a valid doctor’s prescription and an import permit, where applicable.

Indian Pharma Network (IPN) can source MEIYOUHENG from reliable channels across the world and facilitate supply to patients, doctors, and hospitals, offering worldwide access to this treatment under applicable legal provisions. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address from New Delhi, India, after legal requirements are fulfilled.

For Meiyouheng cost in India and availability, contact IPN at WhatsApp: +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@indianpharmanetwork.in.

Global Approval Status:

Meiyouheng (becotatug vedotin) has been approved for the treatment of EGFR-driven recurrent or metastatic nasopharyngeal carcinoma:

• China: The National Medical Products Administration (NMPA) granted conditional marketing approval on 30 October 2025 for adults with recurrent or metastatic nasopharyngeal carcinoma who have failed at least two lines of systemic chemotherapy and prior PD-1/PD-L1 inhibitor therapy. This made becotatug vedotin the first EGFR-targeted ADC approved for marketing anywhere in the world, underscoring its first-in-class status.
• United States: Becotatug vedotin is not approved in the United States. However, the US Food and Drug Administration (FDA) has granted it Fast Track designation and Orphan Drug designation for nasopharyngeal carcinoma.

Approval in China was supported by clinical studies in heavily pretreated R/M NPC. In a multicenter, single-arm phase IIa study (part of trial NCT05126719), patients received becotatug vedotin intravenously every 3 weeks. The study reported an independent review committee-assessed objective response rate (ORR) of approximately 42% and a disease control rate (DCR) of about 81%, with a median duration of response of around 8.0 months and median progression-free survival of about 5.8 months. Median overall survival reached approximately 15.8 months across patients and around 25.2 months in the 2.3 mg/kg group. In a randomized, controlled study comparing becotatug vedotin with chemotherapy in pre-heavily treated R/M NPC, the ADC showed a longer median progression-free survival (about 5.8 months vs. 2.8 months) and a trend toward improved overall survival, while maintaining a manageable safety profile. The most commonly reported treatment-related adverse events included pruritus, rash, and hypoesthesia.

Becotatug vedotin was developed by Lepu Biopharma (through Shanghai Miracogen Inc.). It is also being studied in additional indications and combinations — for example, in combination with the PD-1 inhibitor pucotenlimab (Puyouheng) in squamous cell carcinoma of the head and neck, and in other EGFR-expressing tumors such as colorectal cancer.

Note: Approval and marketing status vary by country. As of the current publicly available information, Meiyouheng is approved in China and is not approved or commercially marketed in India.

What is the generic name for the brand drug Meiyouheng?

Becotatug vedotin (also known by the development code MRG003) is the generic name for the brand drug Meiyouheng.

What is Meiyouheng used for?

Meiyouheng (becotatug vedotin) is used for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) who have failed at least two lines of systemic chemotherapy and prior PD-1/PD-L1 inhibitor therapy.

Who develops and manufactures Meiyouheng?

Meiyouheng was developed by Lepu Biopharma Co., Ltd., through its subsidiary Shanghai Miracogen Inc. Commercial ADC manufacturing has been supported by BioDlink.

What type of medicine is becotatug vedotin?

Becotatug vedotin is an antibody-drug conjugate (ADC) — an EGFR-targeted monoclonal antibody linked to the cytotoxic payload monomethyl auristatin E (MMAE) via a valine-citrulline linker. It is the world’s first EGFR-targeted ADC to be approved.

Is Meiyouheng approved by the FDA?

As of current publicly available information, Meiyouheng is not approved in the United States. The FDA has granted it Fast Track and Orphan Drug designations for nasopharyngeal carcinoma. It is approved in China.

Where is Meiyouheng approved?

Meiyouheng received conditional marketing approval in China from the NMPA on 30 October 2025 for recurrent or metastatic nasopharyngeal carcinoma.

What strength and dosage form is available?

Meiyouheng is an injection given by intravenous infusion. The clinical dose is 2.3 mg/kg once every 3 weeks, administered under the supervision of a qualified oncologist.

What are the most common side effects of Meiyouheng?

The most commonly reported treatment-related side effects include pruritus (itching), rash, and hypoesthesia (numbness or reduced sensation). A decrease in white blood cell count was among the more common higher-grade effects. Patients should report any persistent or severe symptoms to their physician.

How does Meiyouheng import in India work?

Meiyouheng (becotatug vedotin) import in India is possible through the Named Patient Program (NPP) — on behalf of an individual patient with a valid doctor’s prescription. Indian Pharma Network (IPN) helps manage the process, including documentation, approvals, and delivery, so the medicine reaches the patient safely and legally.

Who is a reliable Meiyouheng supplier in India?

Indian Pharma Network (IPN) facilitates compliant access to Meiyouheng (becotatug vedotin) in India through global sourcing channels and structured documentation support for eligible patients, in accordance with applicable regulatory provisions.

How much does Meiyouheng cost in India?

Meiyouheng is not yet approved or marketed in India, but patients can legally access it through the Named Patient Program. Prices may vary over time due to market and regulatory factors. For the latest Meiyouheng (becotatug vedotin) cost in India, call +91 96548 60915 or WhatsApp +91 98104 69557 or email info@indianpharmanetwork.in.

Can Meiyouheng be accessed in SAARC countries?

Yes. In addition to Gulf countries, Meiyouheng can be accessed through import provisions such as the Named Patient Program in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). IPN can help facilitate compliant supply where permitted by local regulations.

Is it safe to buy Meiyouheng injection online in India?

Yes, one can buy Meiyouheng (becotatug vedotin) in India through Indian Pharma Network (IPN), as this product is not yet registered or available in the country. IPN can help facilitate the import of Meiyouheng through legal channels, with prescriptions checked by registered pharmacists.

Can Meiyouheng be delivered to my treating hospital?

Yes. IPN can facilitate delivery of Meiyouheng to the patient’s treating hospital across major Indian cities, under the Named Patient Program, with a valid doctor’s prescription and import permit where applicable. Leading hospitals include AIIMS Delhi, Sir Ganga Ram Hospital, Medanta – The Medicity, Apollo Hospitals Chennai, Christian Medical College (CMC), PGIMER, Kidwai Memorial Institute of Oncology, Adyar Cancer Institute, Amrita Hospital, Artemis Hospital, Safdarjung Hospital, Kauvery Hospital, Sri Ramachandra Medical Centre, Cytecare Cancer Hospital, MIOT International, SCTIMST, NIMS Hospital, KIMS Hospitals, AIG Hospitals, Bombay Hospital, Lilavati Hospital, Care Hospitals, Narayana Health City, Jaslok Hospital, Yashoda Hospitals, Fortis Memorial Research Institute, Kokilaben Dhirubhai Ambani Hospital, P. D. Hinduja Hospital, Manipal Hospitals, Aster Medcity, Indraprastha Apollo Hospital, King George’s Medical University (KGMU), Shalby Hospitals, Tata Memorial Centre, HCG Cancer Center, Basavatarakam Indo-American Cancer Hospital, Cancer Institute (WIA), Max Healthcare, and Rajiv Gandhi Cancer Institute & Research Centre.

What are the storage conditions for Meiyouheng injection?

Storage and handling should follow the approved product labeling. As an ADC injection, it is typically stored refrigerated and protected from light, and is reconstituted/prepared and administered by trained healthcare professionals. Always follow the storage and handling instructions provided with the dispensed product and keep out of the reach of children.